Get the Daily Brief
Latest Biotech News
Prime Editing Shows Promise Against Rare Neurodevelopmental Disorders
Researchers from the Broad Institute and Jackson Laboratory utilized prime editing—a precision CRISPR-derived gene editing technology—to correct multiple ATP1A3 gene mutations responsible for...
Alkermes Advances Narcolepsy Treatment With Phase 2 Success
Alkermes reported positive Phase 2 results for alixorexton, an orexin receptor agonist targeting narcolepsy type 1. The oral drug demonstrated statistically significant improvements in wakefulness...
Danaher Posts Solid Q2 Growth Fueled by Bioprocessing Surge
Danaher reported Q2 revenues of $5.94 billion, reflecting a 4% increase year over year and surpassing analyst estimates. Growth was driven primarily by an 8% revenue rise in its biotechnology...
Jura Bio Debuts AI-Driven Antibody Design Platform
Jura Bio introduced VISTA, an AI-controlled data loop system designed to accelerate de novo antibody design for cancer therapeutics. The platform integrates generative modeling, high-throughput...
UCSF Study Identifies Anticancer Drug Combo for Alzheimer’s Disease
Scientists at UCSF and Gladstone Institutes used computational approaches to identify a combination of two FDA-approved anticancer drugs, letrozole and irinotecan, which reversed Alzheimer’s...
University of Oklahoma Secures $2.8M to Study Friedrich’s Ataxia Genetics
The University of Oklahoma team led by Sanjay Bidichandani received a $2.8 million Department of Defense grant to investigate genotype diversity in Friedrich’s ataxia. Using long-read sequencing,...
OxNanopore Reports 25% Revenue Surge on Sequencing Demand
Oxford Nanopore Technologies reported preliminary H1 2025 revenues of approximately £105 million, representing a 25% year-over-year increase driven by strong growth in research and applied markets...
Omega Funds Closes $647M Biotech Venture Capital Fund
Boston and Geneva-based biotech investor Omega Funds secured $647 million for its eighth venture capital fund, matching the size of its 2021 raise. The fund targets innovative life sciences...
Sarepta gene therapy standoff: shipments paused amid FDA safety probe
Sarepta Therapeutics has temporarily halted all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following mounting safety concerns and an FDA request. The pause follows...
Sanofi secures early vaccine tech with $1.15 billion Vicebio acquisition
Sanofi has agreed to acquire the vaccine-focused biotech Vicebio for $1.15 billion upfront, plus $450 million in milestone payments, expanding its respiratory syncytial virus (RSV) vaccine...
Prime editing reverses rare childhood brain disorder in mice, opens therapeutic avenues
Researchers from the Broad Institute and Jackson Laboratory have successfully applied prime genome editing to correct multiple mutations underlying alternating hemiplegia of childhood (AHC), a...
Biogen commits $2 billion to expand North Carolina manufacturing campuses
Biogen announced a $2 billion investment over the next three years to expand and modernize its manufacturing facilities in North Carolina’s Research Triangle Park. The expansion will enhance...
AstraZeneca pledges $50 billion toward US manufacturing and R&D growth
AstraZeneca confirmed plans to invest $50 billion in the United States by 2030, focusing on manufacturing and research facilities expansion. The commitment includes a $4 billion new factory in...
Alkermes advances narcolepsy treatment with positive mid-stage trial results
Alkermes reported favorable Phase 2 data for alixorexton, an orexin receptor agonist aimed at treating narcolepsy type 1, showing significant improvements in wakefulness and reductions in daytime...
FDA appoints former biotech exec George Tidmarsh as new drug review chief
The FDA has named George Tidmarsh, a Stanford-trained oncologist and experienced biopharma CEO, as the director of the Center for Drug Evaluation and Research (CDER). Tidmarsh brings extensive...
New polygenic risk scores enable childhood prediction of adult obesity
Scientists have developed multi-ancestry polygenic risk scores (PRS) that predict an individual’s likelihood of developing adult obesity based on genetic variants present early in life. An...
Radiotherapy induces genomic and immune shifts in breast cancer tumors
A Phase 2 clinical trial reversing standard breast cancer treatment order has revealed how radiotherapy alone impacts tumor biology. Delivering radiation before surgery allowed researchers at MD...
Orbital Therapeutics enters CAR-T field with circular RNA preclinical data
Orbital Therapeutics, a secretive startup pioneering circular RNA technology, released its first preclinical data demonstrating in vivo CAR-T cell therapy potential in non-human primates. The...
Sanofi Pays $1.15B Upfront for Vaccine Biotech Vicebio Acquisition
Sanofi is advancing its respiratory vaccine pipeline by acquiring London-based Vicebio for $1.15 billion upfront, with additional payments possible based on clinical milestones. Vicebio's lead...
Sarepta’s Duchenne Gene Therapy Shipments Paused Amid FDA Dispute
Sarepta Therapeutics reversed its previous refusal and agreed to temporarily pause shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), following a request from the FDA....